News | News By Subject | News by Disease News By Date | Search News

Irritable Bowel Syndrome/Colitis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Synthetic Biologics (SYN)'s IBS-C Drug Meets All Endpoints in Second Phase II Study     1/20/2016
EXCLUSIVE: Ironwood (IRWD), AstraZeneca PLC (AZN) IBS-C Drug Will File in China Next Year, CEO Tells BioSpace (DHX)     7/9/2015
Exciting Time for Biotech in New Jersey     6/29/2015
Your Analyst-Vetted Guide to the Five Blockbuster Drugs the FDA May Approve This Summer     5/28/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Ardelyx Inc. (ARDX) Looks Good After Tenanpanor Results: Citi Analysts     10/1/2014
Ardelyx Inc. (ARDX) Irritable Bowel Syndrome Drug Succeeds In Phase 2b Trial     10/1/2014
Salix Pharmaceuticals, Ltd. (SLXP) Surges On Encouraging Phase 3 Results For Rifaximin; Stock Up +13.51% At Market Close (July 1, 2014)     7/2/2014
Furiex Pharmaceuticals, Inc. (FURX) Shares Double As Irritable Bowel Drug Succeeds In Phase 3 Trials     2/5/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) Says Death of MS Patient Not Related to Drug     10/9/2013
FDA Panel Backs NPS Pharmaceuticals, Inc. (NPSP)'s Drug for Short Bowel Syndrome     10/17/2012
FDA Approves Ironwood Pharmaceuticals' Drug for IBS     8/30/2012
Ironwood Pharmaceuticals Preps Drug for Irritable Bowel Syndrome     8/22/2012

News from Around the Web
5 Daring Biopharmas Mixing Drugs With Marijuana     2/6/2017
Breath Test May Help Diagnose Irritable Bowel Syndrome, Published In Alimentary Pharmacology And Therapeutics     5/11/2016
Do Genes Link Headaches, Irritable Bowel Syndrome? Istanbul University Study     2/24/2016
Large Proportion Of IBS Patients Are Vitamin D Deficient, University of Sheffield Study     12/28/2015
Some Drugs Less Harsh Than Others for IBS, Cedars-Sinai Medical Center Study Says     3/27/2012
Red Meat 'Increases Risk of Bowel Cancer' - World Cancer Research Fund Study Suggests     5/24/2011
Mint Relieves Bowel Disorder, University of Adelaide Study     4/19/2011
Linaclotide Provides Improvements in Abdominal Symptoms in Patients With IBS, Severe Abdominal Pain: Ironwood Pharmaceuticals Study Presented at UEGW     10/29/2010
Structural Brain Alterations in Patients With Irritable Bowel Syndrome Discovered, McGill University and University of California, Los Angeles (UCLA) Study     7/23/2010
Hypnotherapy 'Can Help' Irritable Bowel Syndrome, Gloucestershire Royal Hospital Study     3/18/2010
St. John's Wort Not Helpful Treatment For Irritable Bowel Syndrome, Mayo Clinic Researchers Say     1/4/2010
Scientists Make "Sugar Bug" Drug For Bowel Disease, Institute Of Food Research Study     8/21/2009
Review Of Probiotic Trial Research Finds Only Bifantis Able To Claim Efficacy For IBS Symptoms, Northwestern University Study     3/23/2009
An Antidepressant May Calm An Irritable Bowel, McMaster University Study     2/27/2009
Shedding Light On Cause Of Bowel Disease, University of Edinburgh Study     12/19/2008

Press Releases
Zealand Pharma  (ZEAL.CO) Release: Patient Recruitment Completed For Phase II Trial With Glepaglutide For Treatment Of Short Bowel Syndrome     2/6/2017
Synthetic Biologics (SYN) Release: Company Confirms Key Features Of Pivotal Phase 2b/3 Trial Of SYN-010 Pursuant To Consultations With FDA     1/19/2017
Axim Biotech Release: Company Enters IBS Clinical Trial For Canchew CBD Chewing Gum     1/19/2017
Axim Biotech Enters IBS Clinical Trial For Canchew CBD Chewing Gum     1/18/2017
Synergy Pharma Announces Positive Results In First Phase III Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)     12/9/2016
Axim Biotech Receives Medical Ethical Committee Approval To Begin IBS Trial For Canchew Plus Cbdgum     12/6/2016
Axim Biotech Begins PK/PD Studies With CanChew Plus CBD Gum For IBS Symptoms In Suffering Patients     11/1/2016
Aerpio Initiates Phase Ia Study Of AKB-4924, A First In Class Once-Daily, Orally Administered HIF-1 Stabilizer, In Development To Treat Inflammatory Bowel Disease (IBD)     9/26/2016
Synthetic Biologics (SYN) Announces Completion Of End Of Phase 2 Meeting With FDA For SYN-010, Intended For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)     8/2/2016
Synthetic Biologics (SYN) To Report Second Quarter 2016 Operational Highlights And Financial Results On August 3, 2016     7/26/2016
Allergan (AGN) Receives Positive Opinion For Truberzi (Eluxadoline) For Treatment Of Irritable Bowel Syndrome With Diarrhoea (IBS-D) In Adults     7/25/2016
Synergy Pharma Provides Update On Ongoing FDA Review Of Plecanatide CIC NDA And IBS-C Clinical Development Program     7/15/2016
Medgenics, Inc. Obtains Rights To First-In-Class Biologic For Severe Pediatric Onset IBD     6/6/2016
Synthetic Biologics (SYN) Announces Detailed Data From Two SYN-010 Phase 2 Clinical Trials For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)     5/23/2016
Ferring Pharma And North Zealand University Hospital Announce eHealth Collaboration Aimed At Transforming IBD Patient Care     5/20/2016

//-->